Dashboard
Manage Tickers

CLRB


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-friday-cellectar-biosciences-announces-plan-to-restate-financials-delays-10-q-filing-and-receives-nasdaq-non-compliance-notification
Reported Friday, Cellectar Biosciences Ann...
08/26/2024 07:38:39

The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in...

cellectar-biosciences-says-its-cash-balance-of-259m-as-of-june-30-2024-when-combined-with-the-194m-raised-in-july-is-adequate-to-fund-its-basic-budgeted-operations-into-the-second-quarter-of-2025
Cellectar Biosciences Says Its Cash Balanc...
08/13/2024 10:42:11

gold-moves-higher-coca-cola-increases-fy24-forecast
Gold Moves Higher; Coca-Cola Increases FY2...
07/23/2024 18:32:19

why-comcast-shares-are-trading-lower-by-6-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Comcast Shares Are Trading Lower By 6%...
07/23/2024 17:21:51

crude-oil-down-2-ge-aerospace-earnings-top-views
Crude Oil Down 2%; GE Aerospace Earnings T...
07/23/2024 16:03:18

cancer-focused-cellectar-biosciences-stock-trades-lower-despite-meeting-goal-in-blood-cancer-study
Cancer-Focused Cellectar Biosciences Stock...
07/23/2024 14:49:57

Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 1...

cellectar-biosciences-iopofosine-i-131-exceeds-primary-endpoint-in-waldenstroms-macroglobulinemia-pivotal-study-with-78-of-major-response-patients-remaining-progression-free-at-18-months
Cellectar Biosciences' Iopofosine I 131 Ex...
07/23/2024 10:51:50

    56.4% major response rate exceeded 20% primary endpoint ·    98.2% disease control rate achieved in heavily pretreated pati...

cellectar-biosciences-generates-194m-potential-for-additional-733m-through-new-warrants
Cellectar Biosciences Generates $19.4M, Po...
07/22/2024 10:52:05

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, developmen...

cellectar-biosciences-partners-with-city-of-hope-cancer-center-to-focus-on-clinical-development-of-cellectars-lead-radioconjugate-asset-iopofosine-i-131-in-mycosis-fungoides-initiation-is-planned-for-late-2024-or-early-2025
Cellectar Biosciences Partners With City O...
05/29/2024 10:42:29

cellectar-biosciences-files-300m-mixed-securities-shelf
Cellectar Biosciences Files $300M Mixed Se...
05/24/2024 20:49:10

cellectar-biosciences-cash-and-cash-equivalents-as-of-march-31-2024-was-40m-that-is-expected-to-provide-cash-runway-into-fourth-quarter-of-2024
Cellectar Biosciences' Cash and Cash Equiv...
05/14/2024 10:48:39

cellectar-biosciences-q1-2024-gaap-eps-074-misses-056-estimate
Cellectar Biosciences Q1 2024 GAAP EPS $(0...
05/14/2024 10:34:59

roth-mkm-maintains-buy-on-cellectar-biosciences-raises-price-target-to-28
Roth MKM Maintains Buy on Cellectar Biosci...
03/28/2024 17:03:11

Roth MKM analyst Jonathan Aschoff maintains Cellectar Biosciences (NASDAQ:CLRB) with a Buy and raises the price target from ...

oppenheimer-reiterates-outperform-on-cellectar-biosciences-raises-price-target-to-12
Oppenheimer Reiterates Outperform on Celle...
03/28/2024 11:33:33

Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and raises the price target ...

cellectar-biosciences-says--cash-and-cash-equivalents-of-96m-and-funds-generated-by-warrants-exercised-in-2023-of-229m-is-expected-to-provide-cash-runway-into-q4-2024
Cellectar Biosciences Says Cash and Cash ...
03/27/2024 10:52:03

cellectar-biosciences-q4-eps-040-beats-059-estimate
Cellectar Biosciences Q4 EPS $(0.40) Beats...
03/27/2024 10:51:27

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of...

earnings-scheduled-for-march-27-2024
Earnings Scheduled For March 27, 2024
03/27/2024 09:02:44

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

earnings-preview-for-cellectar-biosciences
Earnings Preview For Cellectar Biosciences
03/26/2024 17:00:44

cellectar-biosciences-is-an-attractive-acquisition-target-according-to-this-analyst---heres-why
Cellectar Biosciences Is An 'Attractive Ac...
03/04/2024 18:48:03

Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, ach...

roth-mkm-reiterates-buy-on-cellectar-biosciences-maintains-20-price-target
Roth MKM Reiterates Buy on Cellectar Biosc...
03/04/2024 16:44:46

Roth MKM analyst Jonathan Aschoff reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Buy and maintains $20 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION